Sievers, Elisabeth, Trautmann, Marcel ORCID: 0000-0002-5842-1196, Kindler, Dagmar, Huss, Sebastian, Gruenewald, Inga, Dirksen, Uta, Renner, Marcus, Mechtersheimer, Gunhild, Pedeutour, Florence, Aman, Pierre, Nishio, Jun, Schildhaus, Hans-Ulrich, Kirfel, Jutta, Schirmacher, Peter, Wardelmann, Eva, Buettner, Reinhard and Hartmann, Wolfgang ORCID: 0000-0002-7609-5021 (2015). SRC inhibition represents a potential therapeutic strategy in liposarcoma. Int. J. Cancer, 137 (11). S. 2578 - 2589. HOBOKEN: WILEY. ISSN 1097-0215

Full text not available from this repository.

Abstract

Liposarcomas (LS) are the most common malignant mesenchymal tumors, with an overall long-term mortality rate of 60%. LS comprise three major subtypes, i.e., well-differentiated/dedifferentiated liposarcoma (WDLS/DDLS), myxoid/round cell liposarcoma (MLS) and pleomorphic liposarcoma (PLS). Aiming at the preclinical identification of novel therapeutic options, we here investigate the functional significance of SRC in primary human LS and in LS-derived cell lines. Immunohistochemical and Western blot analyses reveal relevant levels of activated p-(Tyr416)-SRC in LS of the different subtypes with particular activation in MLS and PLS. Dysregulation of the SRC modifiers CSK and PTP1B was excluded as major reason for the activation of the kinase. Consistent siRNA-mediated knockdown of SRC or inhibition by the SRC inhibitor Dasatinib led to decreased proliferation of LS cell lines of the different subtypes, with MLS cells reacting particularly sensitive in MTT assays. Flow cytometric analyses revealed that this effect was due to a significant decrease in mitotic activity and an induction of apoptosis. SRC inhibition by Dasatinib resulted in dephosphorylation of SRC itself, its interacting partners FAK and IGF-IR as well as its downstream target AKT. Consistent with a particular role of SRC in cell motility, Dasatinib reduced the migratory and invasive potential of MLS cells in Boyden chamber and Matrigel chamber assays. In summary, we provide evidence that SRC activation plays an important role in LS biology and therefore represents a potential therapeutic target, particularly in MLS and PLS.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Sievers, ElisabethUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trautmann, MarcelUNSPECIFIEDorcid.org/0000-0002-5842-1196UNSPECIFIED
Kindler, DagmarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huss, SebastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gruenewald, IngaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dirksen, UtaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Renner, MarcusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mechtersheimer, GunhildUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pedeutour, FlorenceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aman, PierreUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nishio, JunUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schildhaus, Hans-UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kirfel, JuttaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schirmacher, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wardelmann, EvaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buettner, ReinhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hartmann, WolfgangUNSPECIFIEDorcid.org/0000-0002-7609-5021UNSPECIFIED
URN: urn:nbn:de:hbz:38-386057
DOI: 10.1002/ijc.29645
Journal or Publication Title: Int. J. Cancer
Volume: 137
Number: 11
Page Range: S. 2578 - 2589
Date: 2015
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1097-0215
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
RECEPTOR TYROSINE KINASES; MYXOID LIPOSARCOMA; DEDIFFERENTIATED LIPOSARCOMA; FAMILY KINASES; ACTIVATED SRC; PLEOMORPHIC LIPOSARCOMA; SARCOMA-CELLS; HUMAN CANCER; SOFT-TISSUE; PHASE-IIMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/38605

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item